Last reviewed · How we verify
FPT-20
FPT-20 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
FPT-20 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | FPT-20 |
|---|---|
| Sponsor | Trieu, Nguyen Thi, M.D. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, FPT-20 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism of action is primarily used to treat type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |